Skip to content
Screener

Aclaris Therapeutics ACRS Investing Cash Flow

Investing Cash Flow at other companies

Incyte logo
IncyteINCY
-$51.79M-174%
Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
-$144.85M-3,514%
Upstream Bio, Inc. logo
Upstream Bio, Inc.UPB
$15.76M
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$329.93M-366%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
-$144.95M
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$40.68M-23.8%

Other financials

Income statement

See full
Revenue$1.6M-8.3%
Gross profit$1.4M+11.8%
Operating income-$24.2M-31.7%
Net income-$21.5M-39.4%
EPS (diluted)-$0.15-15.4%

Balance sheet

See full
Cash & equivalents$19.2M-24.5%
Total debt$1.9M-21.8%
Total equity$124.6M-5.4%
Total assets$179.7M-5.0%

Cash flow

See full
Operating cash flow-$19.8M-98.6%
CapEx$58.0K+176%
Free cash flow-$19.9M-98.8%

Valuation

See full
Market cap$868.47M+389%
Enterprise value$851.16M+451%
P/S105.7×+95.1×

Profitability

See full
Gross margin79.5%-6.3pp
Operating margin-1,050.2%+266pp
Net margin-921.5%+161pp
FCF margin-756.5%

Returns & leverage

See full
Return on equity-59.1%-17.4pp
Debt / equity0.0×
Current ratio3.5×-0.4×

Where this comes from

Reported directly by Aclaris Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The source filing: Aclaris Therapeutics’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:32 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-057202
Line itemThree Months Ended / March 31, 2026Three Months Ended / March 31, 2025
Purchases of marketable securities(51,669)(9,996)
Proceeds from sales and maturities of marketable securities20,75029,991
Payments of deferred transaction consideration for in-licensed assets(833)
Net cash (used in) provided by investing activities(30,932)19,119
Cash flows from financing activities:
Proceeds from issuance of common stock under the at-the-market sales agreement, net of issuance costs57,880
Payments of employee withholding taxes related to restricted stock unit award vesting(250)(275)
Proceeds from exercise of employee stock options and the issuance of stock151

Item 1. Financial Statements

FAQ

What is Aclaris Therapeutics's investing cash flow?
Aclaris Therapeutics (ACRS) reported investing cash flow of -$30.93M in Q1 2026.
How has Aclaris Therapeutics's investing cash flow changed year-over-year?
Aclaris Therapeutics's investing cash flow decreased by 261.8% year-over-year, from $19.12M to -$30.93M.
What is the long-term trend for Aclaris Therapeutics's investing cash flow?
Over 2 years (2021 to 2025), Aclaris Therapeutics's investing cash flow has grown at a -46.3% compound annual growth rate (CAGR), from -$167.63M to $48.37M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Ask your AI about Aclaris Therapeutics's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude